Medivation PT Raised to $62.00 (MDVN)
Equities researchers at Barclays boosted their price objective on shares of Medivation (NASDAQ:MDVN) from $57.00 to $62.00 in a research report issued on Friday, American Banking News.com reports. Barclays’ target price would suggest a potential downside of 12.65% from the stock’s previous close.
Medivation (NASDAQ:MDVN) opened at 70.98 on Friday. Medivation has a one year low of $41.89 and a one year high of $71.25. The stock has a 50-day moving average of $63.65 and a 200-day moving average of $58.69. The company’s market cap is $5.356 billion.
Medivation (NASDAQ:MDVN) last announced its earnings results on Tuesday, November 12th. The company reported ($0.18) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.26) by $0.08. The company had revenue of $108.50 million for the quarter, compared to the consensus estimate of $60.13 million. During the same quarter last year, the company posted ($0.06) earnings per share. Medivation’s revenue was down 7.4% compared to the same quarter last year. Analysts expect that Medivation will post $-0.70 EPS for the current fiscal year.
MDVN has been the subject of a number of other recent research reports. Analysts at UBS AG reiterated a “positive” rating on shares of Medivation in a research note to investors on Wednesday, December 4th. Separately, analysts at Credit Suisse raised their price target on shares of Medivation from $77.00 to $80.00 in a research note to investors on Wednesday, November 13th. They now have an “outperform” rating on the stock. Finally, analysts at Maxim Group raised their price target on shares of Medivation from $71.00 to $75.00 in a research note to investors on Wednesday, November 13th. They now have a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and twelve have given a buy rating to the company. Medivation currently has a consensus rating of “Buy” and an average price target of $67.20.
Medivation, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapies.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.